FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso peptide · FOXO4 DRI
A synthetic retro-inverso peptide studied as a senolytic that targets senescent cells in aging research.
FOXO4-DRI at a glance
| Name | FOXO4-DRI |
|---|---|
| Also known as | FOXO4-D-Retro-Inverso peptide, FOXO4 DRI |
| Category | Longevity |
| Type | Peptide |
| Sequence | Retro-inverso peptide based on a FOXO4 interaction motif |
| Typical dose | Reported in animal studies on a per-kilogram basis; no established human dose |
| Frequency | Intermittent dosing (e.g., several times over a period) in animal work |
| Route | Subcutaneous or intraperitoneal injection (animal research) |
| Half-life | Not well characterized in humans. |
Overview
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 protein and p53 inside senescent (aged, non-dividing) cells. It is commonly cited in the research literature for context on senolytics - agents intended to selectively remove senescent cells. The concept comes largely from a single line of mouse research; human clinical data do not exist, and it remains an experimental tool.
How it’s thought to work
- Designed to interfere with FOXO4-p53 binding in senescent cells.
- Aims to release p53 to trigger apoptosis selectively in those cells.
- The retro-inverso design is intended to improve stability against enzymes.
- Proposed to reduce senescent-cell burden associated with aging.
Researched uses
- Senescent-cell clearance in mouse models
- Aging and tissue-function research
- Chemotherapy-related senescence studies
- General senolytic mechanism investigation
Commonly cited protocol
| Typical dose | Reported in animal studies on a per-kilogram basis; no established human dose |
|---|---|
| Frequency | Intermittent dosing (e.g., several times over a period) in animal work |
| Route | Subcutaneous or intraperitoneal injection (animal research) |
| Notes | Human protocols are not established; figures are extrapolated from rodent studies. |
Reconstitution
Commonly a 10 mg vial; 10 mg in 2 mL gives 5 mg/mL, so a 1 mg dose is about 4 units on a U-100 syringe. No validated human dose exists.
FOXO4-DRI dosage calculator
The calculator below is pre-filled with FOXO4-DRI’s commonly cited vial size and dose. Adjust the vial amount, bacteriostatic water, or dose to match your own vial — it will show the exact insulin-syringe units to draw, the concentration, and how many doses the vial holds.
Add 2 mL of bacteriostatic water to your 10 mg vial. That gives you about 10 doses of 1000 mcg. For each dose, draw 20 units into a 100-unit insulin syringe.
See the full FOXO4-DRI dosing chart (units for every dose & water amount), or open the full peptide calculator →
Cautions
- Not approved for any use; a purely experimental research chemical.
- No human clinical data exist.
- Senolytic mechanisms can affect healthy cells; safety is unknown.
- Evidence rests on limited preclinical work.
FOXO4-DRI FAQ
What is FOXO4-DRI?
A synthetic retro-inverso peptide studied as a senolytic that targets senescent cells in aging research.
How does FOXO4-DRI work?
Designed to interfere with FOXO4-p53 binding in senescent cells. Aims to release p53 to trigger apoptosis selectively in those cells. The retro-inverso design is intended to improve stability against enzymes. Proposed to reduce senescent-cell burden associated with aging.
What is FOXO4-DRI used for?
Senescent-cell clearance in mouse models; Aging and tissue-function research; Chemotherapy-related senescence studies; General senolytic mechanism investigation.
What is a typical FOXO4-DRI dose?
Reported in animal studies on a per-kilogram basis; no established human dose, Intermittent dosing (e.g., several times over a period) in animal work, Subcutaneous or intraperitoneal injection (animal research). This is a commonly cited figure for context only, not medical advice.
How do you reconstitute FOXO4-DRI?
Commonly a 10 mg vial; 10 mg in 2 mL gives 5 mg/mL, so a 1 mg dose is about 4 units on a U-100 syringe. No validated human dose exists.
What is the half-life of FOXO4-DRI?
Not well characterized in humans.